This guideline is being developed for creating standards for complete and transparent reporting of clinical trials using mesenchymal stromal cells (MSC). It starts with the development of a consensual definition of MSC and will work on MSC characteristics, manufacturing methods and interventions. A scoping review has started and a two-round Delphi consensus method will be used, with the first round planned for November 2021. A face-to-face consensus meeting will follow. The group leading the project plans to publish the reporting guideline as an open-access document in 2022.
- Scoping review results available in the Open Science Framework: https://osf.io/3dsqx
- Protocol published in BMJ Open: https://bmjopen.bmj.com/content/11/10/e054740
Registered: 4 November 2021
Last updated:
Contact: Dr Bernard Thébaud Email: [email protected]